Skip to content

Pumitamig

DRUG15 trials

Sponsors

Bristol-Myers Squibb, BioNTech SE

Conditions

Advanced Renal Cell Carcinoma (RCC)Advanced Solid TumorBreast CancerBreast NeoplasmsExtensive-stage Small-cell Lung CancerHepatocellular Carcinoma (HCC)Lung CancerNon-Small Cell Lung Cancer (NSCLC)

Phase 1

Phase 2

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingNCT06712316
BioNTech SENon-small Cell Lung Cancer
Start: 2025-01-07End: 2030-03-01Target: 1260Updated: 2026-03-17
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
RecruitingNCT06841055
BioNTech SENon-small Cell Lung Cancer
Start: 2025-03-03End: 2028-10-01Target: 60Updated: 2026-03-13
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RecruitingNCT07221149
Bristol-Myers SquibbUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Start: 2026-03-13End: 2032-09-11Target: 690Updated: 2026-04-02
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
RecruitingNCT07221357
Bristol-Myers SquibbUntreated, Unresectable, or Metastatic Colorectal Cancer
Start: 2025-12-31End: 2034-03-11Target: 990Updated: 2026-03-31
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
RecruitingNCT07255404
BioNTech SEPancreatic Ductal Adenocarcinoma (PDAC)
Start: 2025-12-04End: 2028-08-31Target: 105Updated: 2026-01-09
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
RecruitingNCT07297212
BioNTech SERecurrent Glioblastoma
Start: 2026-01-15End: 2029-07-01Target: 75Updated: 2026-03-12
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Not yet recruitingNCT07492680
Bristol-Myers SquibbSolid Tumors
Start: 2026-07-17End: 2032-05-20Target: 260Updated: 2026-03-25

Phase 3

Related Papers